2025 Highlights
Montefiore Einstein Urology
Raising the Bar in Research
and Patient Care
One of America’s Top Urology Programs—Again.
Montefiore Einstein has consistently ranked as one of the nation’s best hospitals by U.S. News & World Report. This year, we’re proud to share that not only did the institution place in the top one percent of all U.S. hospitals in the 2025–2026 rankings, but the urology program itself was ranked #17—a remarkable distinction. Of note, we were cited as one of the highest-performing programs in the country for prostate cancer surgery and for the prevention of outpatient procedural complications. Such recognition, however, only confirmed what we already knew: Together we have built one of the most dynamic, collegial, and hard-working teams in the country.
DATA & STATISTICS
2025 by the numbers
43,390
Office Visits
5,306
Office Procedures
3,622
OR Cases
11,348
New Patients
Innovations and Achievements
Pioneering the future of treatment and care
New roles & additions to our department
Michelle De Jesus Mendez, NP
Nurse Practitioner
Eunice Glee Rolea, NP
Nurse Practitioner
Ansu Varughese-Colon, NP
Nurse Practitioner
Awards and Recognitions
Stanley Boczko, MD
Listed as a Castle Connolly top doctor of urology
Franklin Lowe, MD
Listed as a Castle Connolly top doctor of urology
Mark Schoenberg, MD
Listed as a Castle Connolly top doctor of urology
Kara Watts, MD
Listed as a Castle Connolly top doctor of urology
Clinical Trials
Advancing care through clinical trials
At Montefiore Einstein Urology, we’re committed to finding new and better ways to treat, prevent and improve a wide spectrum of urological conditions and improve urological health. We are leading collaborative basic and translational research along with spearheading numerous clinical trials, including several funded by the National Institutes of Health (NIH).
As a leader in both basic and translational research in erectile and bladder physiology, our team is at the forefront of clinical trials targeting erectile dysfunction and overactive bladder through the innovative naked deoxyribonucleic acid (DNA) gene transfer technique. In partnership with our NCI-designated cancer center, we are actively involved in many GU oncology studies. Through our numerous active clinical trials, our patients can continue to access emerging technologies and innovative treatments that are otherwise unavailable.
RESTORE: An RCT to Evaluate the Efficacy of the Revi System
The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.
Stent Omission After Ureteroscopy and Lithotripsy in the Michigan Urological Surgery Improvement Collaborative
This is a multicenter prospective trial with randomized and observational cohorts assessing patient-reported outcomes and unplanned healthcare utilization following ureteroscopic treatment of renal and ureteral stones, with placement versus omission of a ureteral stent.
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus-Calmette-Guerin
This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy.
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the treatment of participants with IR-NMIBC.
Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also developing a pragmatic approach for improved GEC clinical use and future study.
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body.
Expanded access
Our top-rated urology specialists are now serving more of the Bronx and Westchester, bringing expert care closer to you at seven convenient locations.
Cast your vote
Polls on Doximity close soon. We hope you’ll consider nominating Montefiore Einstein Urology for the U.S. News & World Report Best Hospitals survey.